. The financial statement for the year 2016 did not comply with the Thai Accounting Standard no.18 (revised 2015), Revenue (TAS 18) and clause 14 a(i) of IAS - IE 18. Later, the rectified financial

the SET and the SEC Office. The Form 56-1 did not comply with the Thai Accounting Standard no.18 (revised 2015), Revenue (TAS 18) and clause 14 a(i) of IAS - IE 18. Later, the rectified Form 56-1 was

Office.The Form 56-2 did not comply with the Thai Accounting Standard no.18 (revised 2015), Revenue (TAS 18) and clause 14 a(i) of IAS – IE 18. Later, the rectified Form 56-2 was filed with the SET and the SEC

Reporting Standard on lease agreements (TFRS 16) and revenue from contracts with customers (TFRS 15). • Net foreign exchange losses: was recorded at THB 5 million in Q2/2020 while in Q2/2019, there was a

Deferred Revenue Item Deferred Revenue Item = Deferred revenue from assets monetization to WHABT in 2015 which recognized in the first quarter of 2019 as a result of accounting standard adjustment (TFRS 15

* According to the adoption of Thai Financial Reporting Standard No.9 Financial Instruments since January 1, 2020, the Company reclassified loan from financial institution for the MRT Purple Line Project (the

dividend payment during Q2/2021. • Land, Property and Equipment decreased by THB 26 million mainly due to the depreciation following the Accounting Standard of the regular accounting period. • Other Non

investment in last year. The Company maintained healthy financial position and sturdy debt service capacity with interest-bearing debt-to-equity ratio of 0.56 times. 2019 Outlook Company maintains 2019 outlook

adoption of new financial reporting standards, the acquisition of a new subsidiary and the depreciation of the Thai Baht that affected the value of Company’s overseas assets • Net debt to equity ratio at the

overseas assets • Net debt to equity ratio at the end of 2Q 2020 stood at 0.98x, an increase from 0.48x on 31 December 2019 2Q 2020 SIGNIFICANT EVENTS Impacts of Coronavirus Disease 2019 (COVID–19) COVID-19